The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.

An absorbent composite includes a porous base layer, a core layer, and a superabsorbent laminate layer. The core layer has a fluff pulp layer and superabsorbent polymer particles. The core layer is disposed on the base layer. The superabsorbent laminate layer is disposed on the core layer. The base layer, the core layer, and the superabsorbent laminate layer are compressed together and embossed under heat and pressure to form a plurality of embossed depressions. The embossed depressions are arranged across a major surface area of the superabsorbent laminate layer. The embossed depressions extend through the composite from the superabsorbent laminate layer and into the core layer and the base layer. A thin, soft, and pliable absorbent composite suitable for a variety of applications including wound care is thereby provided.

A system, method, and apparatus are disclosed for dressing a wound. The apparatus comprises a liquid and gas permeable transmission layer, an absorbent layer for absorbing wound exudate, the absorbent layer overlying the transmission layer, a gas impermeable cover layer overlying the absorbent layer and comprising a first orifice, wherein the cover layer is moisture vapor permeable.

The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.

A nasal drip pad apparatus for use on an individual. The apparatus includes a drip pad assembly positioned configured to be positioned underneath an individual's nose and a string forming configured to form a pair of loops. One of the loops is placed around one of the patient's ears and the other one of the loops is placed around the other one of the patient's ears.

The present invention relates to a wound dressing material comprising a fibrillated acellular dermis matrix and a biodegradable polymer aqueous solution and, more specifically, to: a wound dressing material comprising 5-20 wt % of a fibrillated acellular dermis matrix, 0.5-5 wt % of a biodegradable polymer, and 75-94.5 wt % of water; and a preparation method therefor.

This invention relates to use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule, based on the total weight of the pharmaceutical compositions. In the sesame oil extract, each of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule is in an amount of 2 to 10% by weight of dry raw material based on the total weight of sesame oil. This invention also relates to a medical dressing for treating diabetic ulcer and corresponding medicine box enclosing the said dressing.

Single layered nonwoven wound dressings containing (1) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (2) about 5% by weight to about 95% by weight (e.g., 5% to 95%) bleached cotton fibers, and (3) about 5% by weight to about 60% by weight (e.g., 5% to 60%) hydrophobic fibers (e.g., polypropylene, nylon); all percentages adding up to 100 wt %. Also, multi-layered nonwoven wound dressings, containing (1) at least one inner layer containing (a) about 50% by weight to about 95% by weight (e.g., 50% to 95) non-scoured, non-bleached greige cotton fibers and (b) about 5% by weight to about 50% by weight (e.g., 5% to 50%) hydrophobic fibers, all percentages adding up to 100 wt %, and (2) at least one outer layer containing (a) about 5% by weight to about 95% by weight (e.g., 5% to 95%) non-scoured, non-bleached greige cotton fibers, (b) about 5% by weight to about 95% by weight (e.g., 5% to 95%) bleached cotton fibers, and (c) about 5% by weight to about 60% by weight (e.g., 5% to 60%) hydrophobic fibers (e.g., polypropylene, nylon); all percentages adding up to 100 wt %.

Medical gauze includes a warp knitted fabric having a warp and weft direction and composed of loops continued in the warp direction. The warp knitted fabric is made of 100% long fiber containing 70% by weight or more of regenerated cellulose-based long fiber. The warp knitted fabric is preferably configured in a marquisette construction. The regenerated cellulose-based long fiber is preferably cuprammonium rayon. Preferably having a width of equal to or greater than 5 mm and equal to or less than 600 mm, and a weight of equal to or greater than 28 g and equal to or less than 290 g per square meter. As the warp knitted fabric is composed of the loops continued in the warp direction and made of 100% long fiber containing 70% by weight or more of the regenerated cellulose-based long fiber, the occurrence of lint can be reduced to improve lint-free performance.

The technology described in this application provides a dressing (as well as uses, systems, and methods including such dressing) that includes a contact layer with a first surface configured to contact a tissue site in a subject and includes a scaffold configured to structurally support the contact layer, where the contact layer includes a bioresorbable material. The dressing may advantageously exhibit protease-modulating activity under physiological conditions.